News Release - Eli Lilly and Company
WEBNov 8, 2023 — News Release. FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems. Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose.
News Release - Eli Lilly and Company
WEBOct 15, 2023 — In a co-primary endpoint, following the lead-in period, participants taking tirzepatide achieved an additional 21.1% mean weight loss. In a secondary endpoint, participants achieved a total mean weight loss of 26.6% (29.2 kg or 64.4 lb.) from study entry over 84 weeks.
Lilly's tirzepatide achieved up to 15.7% weight loss in adults with ...
WEBINDIANAPOLIS, April 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.
News Release - Eli Lilly and Company
WEBAug 27, 2024 — In a clinical study, tirzepatide 5 mg, along with a reduced calorie diet and increased physical activity, achieved an average of 15% weight loss over 72 weeks compared to 3.1% for placebo.
Lilly's tirzepatide delivered up to 22.5% weight loss in adults with ...
WEBApr 28, 2022 — Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1. Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study. 63% of participants taking tirzepatide 15 mg achieved at least 20% body weight reductions as a key secondary endpoint. INDIANAPOLIS, April 28, 2022 ...
News Release - Eli Lilly and Company
WEBMay 13, 2022 — FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 …
News Release - Eli Lilly and Company
WEBJul 27, 2023 — Tirzepatide met the primary endpoint of superior mean percent change in body weight compared to placebo from 36 weeks to 88 weeks, indicating sustained weight loss.
News Release - Eli Lilly and Company
WEBJun 26, 2023 — Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight. In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% at 48 weeks.
News Release - Eli Lilly and Company
WEBDec 11, 2023 — Zepbound™ (tirzepatide) injection is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥ 30 kg/m 2), or overweight (BMI ≥ 27 kg/m 2) with at least one weight-related comorbid condition.
News Release - Eli Lilly and Company
WEBAug 1, 2024 — Tirzepatide significantly improved heart failure symptoms and physical limitations Tirzepatide led to 15.7% weight loss in a combined population of people with …